Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
109,272,143
-
Total 13F shares
-
5,144,044
-
Share change
-
-1,049,305
-
Total reported value
-
$6,944,143
-
Price per share
-
$1.35
-
Number of holders
-
42
-
Value change
-
-$1,456,985
-
Number of buys
-
19
-
Number of sells
-
14
Institutional Holders of ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) as of Q4 2023
As of 31 Dec 2023,
ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) was held by
42 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,144,044 shares.
The largest 10 holders included
Anson Funds Management LP, MORGAN STANLEY, INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, Advisor Resource Council, CIBC WORLD MARKET INC., COMMONWEALTH EQUITY SERVICES, LLC, ROYAL BANK OF CANADA, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
42
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.